Key tumor suppressor genes inactivated by “greater promoter” methylation and somatic mutations in head and neck cancer

Tumor suppressor genes (TSGs) are commonly inactivated by somatic mutation and/or promoter methylation; yet, recent high-throughput genomic studies have not identified key TSGs inactivated by both mechanisms. We pursued an integrated molecular analysis based on methylation binding domain sequencing (MBD-seq), 450K Methylation arrays, whole exome sequencing, and whole genome gene expression arrays in primary head and neck squamous cell carcinoma (HNSCC) tumors and matched uvulopalatopharyngoplasty tissue samples (UPPPs). We uncovered 186 downregulated genes harboring cancer specific promoter methylation including PAX1 and PAX5 and we identified 10 key tumor suppressor genes (GABRB3, HOXC12, PARP15, SLCO4C1, CDKN2A, PAX1, PIK3AP1, HOXC6, PLCB1, and ZIC4) inactivated by both promoter methylation and/or somatic mutation. Among the novel tumor suppressor genes discovered with dual mechanisms of inactivation, we found a high frequency of genomic and epigenomic alterations in the PAX gene family of transcription factors, which selectively impact canonical NOTCH and TP53 pathways to determine cell fate, cell survival, and genome maintenance. Our results highlight the importance of assessing TSGs at the genomic and epigenomic level to identify key pathways in HNSCC, deregulated by simultaneous promoter methylation and somatic mutations.

[1]  Rafael A. Irizarry,et al.  Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..

[2]  Henk M. W. Verheul,et al.  Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors , 2013, Epigenetics.

[3]  K. Kinzler,et al.  Clinicopathological Correlates of Activating GNAS Mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas , 2013, Annals of Surgical Oncology.

[4]  Baris Turkbey,et al.  Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? , 2013, Radiology.

[5]  L. Liau,et al.  Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation , 2013, Nature Genetics.

[6]  Baris Turkbey,et al.  Correlation of magnetic resonance imaging tumor volume with histopathology. , 2012, The Journal of urology.

[7]  Yong Zhang,et al.  Identifying ChIP-seq enrichment using MACS , 2012, Nature Protocols.

[8]  M. Go,et al.  Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients , 2012, Oncogene.

[9]  P. Choyke,et al.  Decision support system for localizing prostate cancer based on multiparametric magnetic resonance imaging. , 2012, Medical physics.

[10]  M. Terry,et al.  Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency based reprogramming , 2012, Oncogene.

[11]  P. Choyke,et al.  11C-Acetate PET/CT in Localized Prostate Cancer: A Study with MRI and Histopathologic Correlation , 2012, The Journal of Nuclear Medicine.

[12]  Z. Herceg,et al.  DNA methylation changes associated with risk factors in tumors of the upper aerodigestive tract , 2012, Epigenetics.

[13]  Jeffrey T Leek,et al.  Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. , 2012, International journal of epidemiology.

[14]  P. Morin,et al.  The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease. , 2011, Cancer research.

[15]  Giovanni Parmigiani,et al.  Integrating diverse genomic data using gene sets , 2011, Genome Biology.

[16]  M. Hebrok,et al.  Elevated Hedgehog/Gli signaling causes β-cell dedifferentiation in mice , 2011, Proceedings of the National Academy of Sciences.

[17]  K. Gunderson,et al.  High density DNA methylation array with single CpG site resolution. , 2011, Genomics.

[18]  Jinshui Fan,et al.  Gene expression pathways of high grade localized prostate cancer , 2011, The Prostate.

[19]  P. V. van Diest,et al.  Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer , 2011, The Journal of pathology.

[20]  R. Gibbs,et al.  Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 , 2011, Science.

[21]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[22]  A. Feinberg,et al.  Increased methylation variation in epigenetic domains across cancer types , 2011, Nature Genetics.

[23]  Martin J. Aryee,et al.  Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences , 2011, BMC Genomics.

[24]  Tao Liu,et al.  Using MACS to Identify Peaks from ChIP‐Seq Data , 2011, Current protocols in bioinformatics.

[25]  Jiang Gu,et al.  Transcription Factors E2A, FOXO1 and FOXP1 Regulate Recombination Activating Gene Expression in Cancer Cells , 2011, PloS one.

[26]  R. Irizarry,et al.  NID2 and HOXA9 Promoter Hypermethylation as Biomarkers for Prevention and Early Detection in Oral Cavity Squamous Cell Carcinoma Tissues and Saliva , 2011, Cancer Prevention Research.

[27]  Jun Yu,et al.  Paired box gene 5 is a novel tumor suppressor in hepatocellular carcinoma through interaction with p53 signaling pathway , 2011, Hepatology.

[28]  J. Califano,et al.  KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses , 2010, International journal of cancer.

[29]  Natalie Jäger,et al.  Genome-wide mapping of DNA methylation: a quantitative technology comparison , 2010, Nature Biotechnology.

[30]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[31]  Rudolf Grosschedl,et al.  Transcription control of early B cell differentiation. , 2010, Current opinion in immunology.

[32]  V. Laudet,et al.  Retinoic acid signaling targets Hox genes during the amphioxus gastrula stage: insights into early anterior-posterior patterning of the chordate body plan. , 2010, Developmental biology.

[33]  Lee E. Edsall,et al.  Human DNA methylomes at base resolution show widespread epigenomic differences , 2009, Nature.

[34]  David Serre,et al.  MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome , 2009, Nucleic acids research.

[35]  M. Suntharalingam,et al.  Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients , 2009, Cancer Prevention Research.

[36]  Giovanni Parmigiani,et al.  A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. , 2009, Cancer research.

[37]  W. Westra.  The Changing Face of Head and Neck Cancer in the 21st Century: The Impact of HPV on the Epidemiology and Pathology of Oral Cancer , 2009, Head and neck pathology.

[38]  A. Feinberg,et al.  Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores , 2008, Nature Genetics.

[39]  R. Kageyama,et al.  Progenitor cell proliferation in the retina is dependent on Notch-independent Sonic hedgehog/Hes1 activity , 2009, The Journal of cell biology.

[40]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[41]  L. Glimcher,et al.  The endoplasmic reticulum stress response in immunity and autoimmunity , 2008, Nature Reviews Immunology.

[42]  J. Manola,et al.  TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.

[43]  D. Neville,et al.  A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxin. , 2007, Protein engineering, design & selection : PEDS.

[44]  M. Busslinger,et al.  Pax5: the guardian of B cell identity and function , 2007, Nature Immunology.

[45]  Victoria Bolós,et al.  Notch signaling in development and cancer. , 2007, Endocrine reviews.

[46]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[47]  V. A. Flørenes,et al.  Pax-5 expression in nonhematopoietic tissues. , 2006, American journal of clinical pathology.

[48]  A. Carvalho,et al.  Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. , 2006, Cancer research.

[49]  C. Roehrborn,et al.  The Cost of Prostate Cancer Chemoprevention: A Decision Analysis Model , 2006, Cancer Epidemiology Biomarkers & Prevention.

[50]  S. Goodman,et al.  Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. , 2006, Journal of the National Cancer Institute.

[51]  G. Mills,et al.  Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward , 2006, Clinical Cancer Research.

[52]  Lori Armstrong,et al.  Genetic testing for susceptibility to breast and ovarian cancer: Evaluating the impact of a direct-to-consumer marketing campaign on physicians' knowledge and practices , 2006, Genetics in Medicine.

[53]  Ariel Whitworth.  New research suggests access, genetic differences play role in high minority cancer death rate. , 2006, Journal of the National Cancer Institute.

[54]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Robert Gentleman,et al.  Local modeling of global interactome networks , 2005 .

[56]  Seon-Young Kim,et al.  PAGE: Parametric Analysis of Gene Set Enrichment , 2005, BMC Bioinform..

[57]  C. Monneret.  Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.

[58]  J. Neilson,et al.  Integration of Notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and differentiation control. , 2005, Developmental cell.

[59]  Anna Lagergren,et al.  Neuroblastoma and pre-B lymphoma cells share expression of key transcription factors but display tissue restricted target gene expression , 2004, BMC Cancer.

[60]  V. Laudet,et al.  Retinoic acid signaling acts via Hox1 to establish the posterior limit of the pharynx in the chordate amphioxus , 2004, Development.

[61]  Minoru Toyota,et al.  Aberrant Promoter Methylation of the Transcription Factor Genes PAX5 α and β in Human Cancers , 2003 .

[62]  A. Bird,et al.  Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals , 2003, Nature Genetics.

[63]  R. Balling,et al.  Pax1 and Pax9 activate Bapx1 to induce chondrogenic differentiation in the sclerotome , 2003, Development.

[64]  C. Hui,et al.  Sonic hedgehog-dependent activation of Gli2 is essential for embryonic hair follicle development. , 2003, Genes & development.

[65]  Y. Benjamini,et al.  Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.

[66]  M. Cantile,et al.  Homeobox genes in normal and malignant cells , 2001, Journal of cellular physiology.

[67]  P. Gruss,et al.  Loss of p53 function through PAX‐mediated transcriptional repression. , 1995, The EMBO journal.

[68]  M. Capecchi,et al.  The role of Hoxa-3 in mouse thymus and thyroid development. , 1995, Development.

[69]  James M. Roberts,et al.  Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. , 2010, Trends in molecular medicine.

[70]  P. Andrades,et al.  Islet yield after different methods of pancreatic Liberase delivery. , 2007, Transplantation proceedings.

[71]  Minoru Toyota,et al.  Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers. , 2003, Cancer research.

[72]  D. Brachman,et al.  Molecular biology of head and neck cancer. , 1994, Seminars in oncology.

[73]  S. Taylor.  Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.